CAR T cells for the long run in aggressive B-cell lymphoma
CAR T cells for the long run in aggressive B-cell lymphoma
About this item
Full title
Author / Creator
Publisher
London: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Since first being reported in 2010,1 CD19-directed chimeric antigen receptor (CAR) T cells have led a revolution in the treatment of B-cell non-Hodgkin lymphomas. [...]the follow-up period was substantially extended, with a median of 40·3 months (IQR 37·8–43·8), and so the Article shows truly long-term patient outcomes. The findings reported by Sch...
Alternative Titles
Full title
CAR T cells for the long run in aggressive B-cell lymphoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2572530151
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2572530151
Other Identifiers
ISSN
1470-2045,1474-5488
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(21)00412-5